- 作者：Massimo Martino1 ; maxmartino@live.com" class="auth_mail" title="E-mail the corresponding author ; Francesco Lanza2 ; Lorenzo Pavesi3 ; Mustafa Ö ; ztü ; rk4 ; Didier Blaise5 ; Rubé ; n Leno Nú ; ñ ; ez6 ; Harry C. Schouten7 ; Alberto Bosi8 ; Ugo De Giorgi9 ; Daniele Generali10 ; Giovanni Rosti11 ; Andrea Necchi12 ; Andrea Ravelli2 ; Carmelo Bengala13 ; Manuela Badoglio14 ; Paolo Pedrazzoli15 ; Marco Bregni16 ; on behalf of the European Group for Blood ; Marrow Transplantation Solid Tumor Working Party
- 关键词：Autologous hematopoietic stem cell transplantation ; High-dose chemotherapy ; High-risk breast cancer
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：22
- 期：3
- 页码：475-481
- 全文大小：1064 K
- •
The prognosis of high-risk BC patients has changed very little in the past 2 decades with the use of conventional chemotherapy.
- •
High-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (AHSCT) is today a safe treatment modality with low toxicity.
- •
The efficacy of HDC and AHSCT for high-risk BC has been an area of intense controversy among the medical oncology community.
- •
Phase II studies suggested that this approach improved long-term disease control.
- •
Preliminary reports from randomized studies did not showed an overall survival benefit.
- •
Nevertheless, HDC might be of potential benefit in subgroups of high-risk BC patients.
- •
As a contribution to this field, we report the results of this approach in a large cohort of high-risk BC patients treated in Europe between 1995 and 2005.